Gut microbes in Crohn's disease: Getting to know you better?

Seamus J. Murphy, Thomas A. Ullman, Maria T Abreu

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

Biomarkers in inflammatory bowel disease (IBD) are needed to help in disease diagnosis, prognosis, and assessment of disease activity. The best serologic markers to date measure antibody responses to normal commensal flora. These antibody responses can provide prognostic information as well as clues to disease pathogenesis. There remains room for additional biomarkers to clarify the diagnosis for certain patients with indeterminate colitis or small bowel Crohn's disease (CD) with protean manifestations. In this issue of the Journal, Adams and colleagues describe the presence of antibodies against Bacteroides vulgatus in CD patients. This additional marker may complement existing disease markers. Future studies should address whether these antibodies can help categorize patients with indeterminate colitis or predict severity of CD.

Original languageEnglish
Pages (from-to)397-398
Number of pages2
JournalAmerican Journal of Gastroenterology
Volume103
Issue number2
DOIs
StatePublished - Feb 1 2008
Externally publishedYes

Fingerprint

Crohn Disease
Colitis
Antibody Formation
Biomarkers
Bacteroides
Antibodies
Inflammatory Bowel Diseases

ASJC Scopus subject areas

  • Gastroenterology

Cite this

Gut microbes in Crohn's disease : Getting to know you better? / Murphy, Seamus J.; Ullman, Thomas A.; Abreu, Maria T.

In: American Journal of Gastroenterology, Vol. 103, No. 2, 01.02.2008, p. 397-398.

Research output: Contribution to journalArticle

Murphy, Seamus J. ; Ullman, Thomas A. ; Abreu, Maria T. / Gut microbes in Crohn's disease : Getting to know you better?. In: American Journal of Gastroenterology. 2008 ; Vol. 103, No. 2. pp. 397-398.
@article{a3838d95a2bd410baa5e08879dfa3152,
title = "Gut microbes in Crohn's disease: Getting to know you better?",
abstract = "Biomarkers in inflammatory bowel disease (IBD) are needed to help in disease diagnosis, prognosis, and assessment of disease activity. The best serologic markers to date measure antibody responses to normal commensal flora. These antibody responses can provide prognostic information as well as clues to disease pathogenesis. There remains room for additional biomarkers to clarify the diagnosis for certain patients with indeterminate colitis or small bowel Crohn's disease (CD) with protean manifestations. In this issue of the Journal, Adams and colleagues describe the presence of antibodies against Bacteroides vulgatus in CD patients. This additional marker may complement existing disease markers. Future studies should address whether these antibodies can help categorize patients with indeterminate colitis or predict severity of CD.",
author = "Murphy, {Seamus J.} and Ullman, {Thomas A.} and Abreu, {Maria T}",
year = "2008",
month = "2",
day = "1",
doi = "10.1111/j.1572-0241.2007.01571.x",
language = "English",
volume = "103",
pages = "397--398",
journal = "American Journal of Gastroenterology",
issn = "0002-9270",
publisher = "Nature Publishing Group",
number = "2",

}

TY - JOUR

T1 - Gut microbes in Crohn's disease

T2 - Getting to know you better?

AU - Murphy, Seamus J.

AU - Ullman, Thomas A.

AU - Abreu, Maria T

PY - 2008/2/1

Y1 - 2008/2/1

N2 - Biomarkers in inflammatory bowel disease (IBD) are needed to help in disease diagnosis, prognosis, and assessment of disease activity. The best serologic markers to date measure antibody responses to normal commensal flora. These antibody responses can provide prognostic information as well as clues to disease pathogenesis. There remains room for additional biomarkers to clarify the diagnosis for certain patients with indeterminate colitis or small bowel Crohn's disease (CD) with protean manifestations. In this issue of the Journal, Adams and colleagues describe the presence of antibodies against Bacteroides vulgatus in CD patients. This additional marker may complement existing disease markers. Future studies should address whether these antibodies can help categorize patients with indeterminate colitis or predict severity of CD.

AB - Biomarkers in inflammatory bowel disease (IBD) are needed to help in disease diagnosis, prognosis, and assessment of disease activity. The best serologic markers to date measure antibody responses to normal commensal flora. These antibody responses can provide prognostic information as well as clues to disease pathogenesis. There remains room for additional biomarkers to clarify the diagnosis for certain patients with indeterminate colitis or small bowel Crohn's disease (CD) with protean manifestations. In this issue of the Journal, Adams and colleagues describe the presence of antibodies against Bacteroides vulgatus in CD patients. This additional marker may complement existing disease markers. Future studies should address whether these antibodies can help categorize patients with indeterminate colitis or predict severity of CD.

UR - http://www.scopus.com/inward/record.url?scp=39049118858&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=39049118858&partnerID=8YFLogxK

U2 - 10.1111/j.1572-0241.2007.01571.x

DO - 10.1111/j.1572-0241.2007.01571.x

M3 - Article

C2 - 18289202

AN - SCOPUS:39049118858

VL - 103

SP - 397

EP - 398

JO - American Journal of Gastroenterology

JF - American Journal of Gastroenterology

SN - 0002-9270

IS - 2

ER -